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Abstract 
Background: Antiretroviral treatment (ART) reduces HIV infectiousness, but the effect of 
early ART on sexual behaviour is unclear.  
Methods: We assessed, within the START randomised trial that enrolled HIV-positive adults 
with CD4>500/mm3, the effect of early (immediate) versus deferred ART on: (i) condomless 
sex with HIV-serodifferent partners (CLS-D); (ii) all condomless sex (CLS); (iii) HIV 
transmission-risk-sex (CLS-D-HIV-risk, defined as CLS-D and: not on ART or started ART 
<6 months ago or viral load(VL)>200c/mL or no VL in past 6 months), during two year 
follow-up. Month-12 CLS-D (2010-2014) was the primary outcome. 
Results: Among 2562 MSM, there was no difference between immediate and deferred arms 
in CLS-D at month 12 [12.6% versus 13.1%; difference (95% CI):-0.4%(-3.1%, 
2.2%),p=0.75] or month 24, or in CLS. Among 2010 heterosexual men and women, CLS-D 
at month 12 tended to be higher in the immediate versus deferred arm [10.8% versus 8.3%; 
difference:2.5%(-0.1%, 5.2%),p=0.062]; the difference was greater at month 24 [9.3% versus 
5.6%; difference:3.7%(1.0%, 6.4%),p=0.007], at which time CLS was higher in the 
immediate arm [20.7% versus 15.7%,p=0.013]. CLS-D-HIV-risk at month 12 was 
substantially lower in the immediate versus deferred arm for MSM [0.2% versus 11.0%; 
difference:-10.7%(-12.5%, -8.9%),p<0.001] and heterosexuals [0.6% versus 7.7%; 
difference:-7.0%(-8.8%, -5.3%),p<0.001], due to viral suppression on ART.  
Conclusions: A strategy of early ART had no effect on condomless sex with HIV-
serodifferent partners among MSM, but resulted in modestly higher prevalence among 
heterosexuals. However, among MSM and heterosexuals, early ART resulted in a substantial 
reduction in HIV-transmission-risk-sex, to a very low absolute level.  
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Introduction  
In 2015, results were published from the START (Strategic Timing of Antiretroviral 
Treatment Trial)1,2 and TEMPRANO3 randomised trials, demonstrating that a strategy of 
immediate ART (regardless of CD4 cell count) for people with diagnosed HIV reduced 
serious morbidity and mortality compared to ART deferral. Guidelines that had previously set 
CD4 thresholds for ART initiation were changed to recommend ART initiation for all adults 
with HIV at any CD4 level.4-6 US guidelines had already recommended such a strategy, 
primarily based on evidence from observational studies.7   
 
Prior to this conclusive evidence of the clinical benefit of early ART, results had been 
accumulating regarding the protective effect of ART on HIV transmission. Initially, a number 
of observational studies demonstrated a marked association between the viral load (VL) of an 
HIV-positive person and the risk of HIV transmission to an HIV-negative partner.8-12 In 
2011, unequivocal evidence came from the HPTN 052 randomised trial, which demonstrated 
that use of early ART for the HIV-positive partner of serodifferent couples was associated 
with a 96% reduction in transmissions to the HIV-negative partner.13 Subsequently, the 
PARTNER14, PARTNER215 and Opposites Attract16 prospective observational studies 
provided crucial information on transmission risk specifically through condomless sex (CLS), 
including anal CLS, among HIV serodifferent heterosexual and MSM couples. In each of 
these studies, there were no within-couple linked HIV transmissions during eligible follow-up 
in which couples reported CLS and the HIV-positive partner was virally suppressed on ART. 
Together these studies have provided the necessary evidence for assurance that HIV-positive 
people on ART with undetectable VL cannot transmit HIV (Undetectable=Untransmittable; 
Prevention Access Campaign).17 
  
As knowledge regarding the protective effect of VL suppression on HIV infectiousness has 
been disseminated and publicized, and in particular since the ‘Swiss Statement’ in 2008,18 it 
has been debated whether such knowledge impacts on sexual behaviour and patterns of 
condom use among people taking ART.19-21 Initially the concern was that if viral suppression 
on ART led merely to a reduction in (rather than elimination of) HIV transmission risk, any 
increase by the HIV-positive individual in CLS with HIV-serodifferent partners (CLS-D) 
could partially negate the benefit of ART.19,20 Recent findings have provided reassurance on 
this point, demonstrating no transmission risk in this context.14-16 However an increase in 
CLS-D associated with ART use may still be concerning in the context of sub-optimal ART 
adherence, infrequent VL monitoring, inaccurate knowledge of personal VL status22 or poor 
knowledge of the importance of viral suppression, a key issue in early treatment.23 
Furthermore, any changes in patterns of CLS overall may have implications for transmission 
of other sexually transmitted infections (STIs). It is also conceivable that reductions in 
condom use among HIV-positive people may affect condom use among HIV-negative people 
with partners of unknown HIV status. 
 
There is, to date, little compelling evidence that ART use leads to higher levels of 
condomless sex among people with HIV. Findings from some observational studies have 
suggested that, in some contexts or subgroups, condom use may be influenced by knowledge 
of viral suppression.24-29 However, in most studies, overall, levels of CLS-D were similar or 
lower among people on ART compared to those not on ART (or among people with 
undetectable compared to detectable VL).28-46 Two randomised trials have provded data on 
this issue;47,48 neither supports the hypothesis that ART use leads to increased CLS-D. 
However, it is important to reeavualte this association as patterns of sexual behaviour may 
have changed with increasing awareness of the protective effect of suppressed VL, 
paritcularly since publication of HPTN 052 in 2011.13 Furtherore, now that the protective 
effect of viral suppression on HIV transmission is assured, it is necessary to consider 
measures additional to CLS-D, that capture sex with risk of HIV-transmission by accounting 
for viral suppression.45,47-49 When considering risk of other STIs, CLS overall is the most 
relevant measure. 
We previously reported on sexual behaviour at enrolment in the START trial.50 We now 
assess, separately among MSM and heterosexual individuals, the effect of a strategy of early 
ART compared to ART deferral on sexual behaviour in the first two years of follow-up, 
considering: CLS-D at month 12 (the pre-defined primary outcome), CLS, CLS-D with risk 
of HIV transmission, and other measures.  
Methods 
Study population 
START was an open-label multicenter randomized trial enrolling 4684 HIV-positive people 
who had never taken ART and who had a CD4 count above 500 cells/μL, from April 2009 to 
December 2013. 1 Individuals were randomised to either start ART immediately (early ART) 
or to defer ART until occurrence of a CD4 cell count below 350 cells/μL or an AIDS event. 
The primary endpoint was serious AIDS or non-AIDS morbidity or mortality. On May 15th 
2015, the Data and Safety Monitoring Board determined that the study question had been 
answered and recommended that ART be offered to all participants. Rate of the primary 
endpoint was lower in the immediate versus deferral arm [hazard ratio (95% CI): 0.43 (0.30, 
0.62) p<0.001].2  
Transmission risk behaviour study 
Participants were asked to self-complete a transmission risk behaviour questionnaire at 
baseline, month 4, and every 12 months subsequently. Sexual activity (vaginal or anal sex) 
during the previous 2 months was ascertained for: men having sex with women; men having 
sex with men; women having sex with men.50 All participants who had a risk behaviour 
questionnaire available within the first two years (at 4, 12, or 24 months) were included in 
this analysis. All information provided after 15th May 2015 was excluded. Sexual behaviour 
measures (two month recall period) were derived at baseline and each follow-up point, 
including: (i) condomless sex with HIV-serodifferent (negative or unknown status) 
partners(s) (CLS-D); (ii) condomless sex (CLS); (iii) HIV transmission risk sex (CLS-D-
HIV-risk) defined as CLS-D plus at least one of: not on ART; started ART <6 months ago; 
most recent VL>200c/mL; no VL in last 6 months. This last measure was intended to capture 
sex with a risk of HIV transmission. If a person having CLS-D was on ART, having started 
ART at least 6 months ago, and had most recent VL (measured within the past 6 months) 
≤200 c/mL, then risk was assumed to be zero. Additional measures included: ≥2 CLS 
partners; ≥3 CLS partners; ≥2 CLS-D partners; ≥3 CLS-D partners; ≥2 times CLS-D; ≥10 
times CLS-D; insertive CLS-D with ejaculation (men only); total number of CLS-D acts (see 
Table 3 footnote for details). Injection drug use transmission risk was defined as having 
injected drugs in the past two months and having shared needles or other equipment with 
someone who had negative/unknown HIV status. Transmission risk beliefs were beliefs 
related to whether a person using HIV treatment who had an undetectable viral load could 
pass on HIV to another person through unprotected sex. Responses of: “cannot” and “much 
less likely” were grouped together in contrast to: “a little less likely”, “just as likely” and 
“more likely”. The pre-specified primary outcome was CLS-D at month 12. Separate analyses 
were pre-specified for MSM, and heterosexual men and women (combined).27 Some 
measures were considered only for MSM, due to low frequency among heterosexual 
participants.  
 
Transmission risk behavior forms were updated early in recruitment. Information on CLS-D 
and CLS-D-HIV-risk was available from original and updated forms; information on all other 
outcomes was available only from the updated version. Participants were included in an 
analysis at a specific time point if the relevant behaviour questionnaire was available; 
treatment of missing values is described in the footnote of Table 3. 
 
Statistical methods 
Baseline characteristics, and ART use and viral suppression over follow-up, were summarised 
according to gender/sexual orientation. Subsequent analyses were carried out separately for: 
MSM; heterosexual men and women combined. Sexual behaviour and attitude measures were 
summarised by time point and randomised arm. An alternative baseline measure excluded 
participants diagnosed with HIV for less than three months who may have been reporting pre-
diagnosis sexual behaviour. Chi-squared tests were used to compare proportions between 
randomised arms at months 4, 12 and 24; Mann-Whitney U tests were used to compare 
number of CLS-D acts among the subgroup of participants who were diagnosed >3 months 
ago and reported CLS-D at baseline. Logistic regression was used to obtain odds ratios for the 
intervention effect on CLS-D prevalence at month 12: unadjusted, adjusted for baseline 
factors, and stratified by baseline factors. Factors considered were: gender (heterosexual 
analysis only); age group (<40; ≥40 years); recruitment setting (low/middle income [Africa, 
Asia, Central/South America]; high income [Europe/Israel; North America; Oceania]; date 
randomised (<2012; ≥2012); time since HIV diagnosis (<0.5 years; ≥0.5 years); education 
level (less than high school; high school or above). Interaction tests were used to assess 
whether the intervention effect differed across subgroups. 
 
In addition, a generalized estimating equation (GEE) logistic model was used in which data 
from months 4, 12 and 24 were combined, with CLS-D as the dependent variable, and time 
point (month 4, 12, 24), randomization arm (immediate; deferred), calendar year (year of 
completion of risk questionnaire, as an ordinal measure) and gender (heterosexual model 
only) as independent variables. An autoregressive correlation structure was used to account 
for repeated responses from individuals. Interaction terms between randomised arm and time 
point were assessed.  
For all comparisons participants were kept in their original randomised group.  
Results 
Of the 4684 HIV-positive people who were randomised, 112 (2.4%) were excluded from 
analysis as they had not completed a transmission risk questionnaire during the two year 
follow-up. Of the remaining 4572 participants there were 2562 MSM, 788 heterosexual men, 
and 1222 women. Baseline characteristics are shown in Table 1.  
 
Sexual behaviour at baseline 
The baseline transmission risk questionnaire was completed by 4504 of 4572 (98.5%) 
participants (original version N=547, updated version N=3957). Prevalence of CLS in the 
past two months was 39.2%, 23.8%, and 28.1% among MSM, heterosexual men and women 
respectively; prevalence of CLS-D was 19.9%, 9.6% and 14.5% respectively. CLS-D-HIV-
risk prevalence was identical to CLS-D prevalence (by definition, as no participants were on 
ART at baseline).  
 
ART use and viral suppression over time 
As of May 15 2015, of 4572 participants, all should have attended the months 4 and 12 visits, 
and 3673 (80.3%) should have attended the month 24 visit. Table 2 shows numbers 
completing the risk behaviour questionnaire by time point and the prevalence of ART use and 
VL ≤200 copies/mL, according to randomised arm and gender/sexual orientation. In the 
immediate arm, the proportion of participants who were on ART remained fairly stable from 
month 4 to month 24, at around 96-98%. Correspondingly, the prevalence of VL ≤200 
copies/mL increased rapidly from baseline to month 4, with some further increase to month 
24. In the deferred arm, the proportion on ART increased steadily over follow-up (as more 
individuals reached eligibility for ART initiation), mirrored by an increase in prevalence of 
viral suppression.  
 
Comparison of sexual behaviour at month 12 between randomised arms 
Table 3 shows sexual behaviour by randomised arm and time point for: (A) MSM and (B) 
heterosexual men and women.  
 
Among MSM, prevalence of CLS-D at month 12 (the primary outcome) was similar in the 
immediate and deferred arms: 12.6% versus 13.1% [difference: -0.4%, 95% CI (-3.1%, 
2.2%), p=0.75 Chi-squared test]. The prevalence of CLS, ≥2 CLS-D partners, ≥3 CLS-D 
partners, ≥2 times CLS-D, >10 times CLS-D and insertive CLS-D with ejaculation at month 
12 did not differ between the arms, nor did number of CLS-D acts among the subgroup 
diagnosed >3 months ago who reported CLS-D at baseline. The prevalence of CLS-D-HIV-
risk at month 12 among MSM was much lower in the immediate versus deferred arms: 0.2% 
versus 11.0% [difference: -10.7%, 95% CI (-12.5%, -8.9%), p>0.001], due to the far higher 
prevalence of VL suppression on ART in the immediate arm. 
 
Among heterosexual men and women there was some evidence that CLS-D at month 12 was 
higher in the immediate versus deferred arm: 10.8% versus 8.3% [difference: 2.5% 95% CI (-
0.1%, 5.2%), p=0.062, Chi-squared test]. A similar pattern was apparent for ≥2 times CLS-D: 
7.1% versus 5.2%, [difference: 1.9%, 95% CI (=0.3%, 4.1%), p=0.089, Chi-squared test]. 
Prevalence of CLS, ≥2 CLS partners, ≥2 CLS-D partners, and insertive CLS-D with 
ejaculation did not differ by arm at month 12, nor did number of CLS-D acts among those 
diagnosed >3 months ago who reported CLS-D at baseline. Although prevalence of CLS-D 
was somewhat higher in the immediate versus deferred arm among heterosexual individuals, 
the prevalence of CLS-D-HIV-risk at month 12 was much lower in the immediate arm: 0.6% 
vs 7.7% [difference:-7.0%, 95% CI (-8.8%, -5.3%), p<0.001, Chi-squared test], due to viral 
suppression on ART. 
 
Comparison of randomised arms according to baseline factors: CLS-D at month 12 
The odds ratio (95% CI) of CLS-D at month 12 for the immediate versus deferred strategy 
was 0.96 (0.76, 1.22) for MSM and 1.34 (0.98, 1.82) for heterosexual men and women (the 
latter adjusted for gender). (Figure 1). Among MSM, there was no evidence that the 
intervention effect on CLS-D varied across subgroups. Among heterosexual men and women, 
the intervention effect (higher CLS-D at month 12 in the immediate versus deferred arm) was 
greater among participants aged <40 years (p=0.035 for interaction).  
 
Time since randomisation and sexual behaviour 
Table 3 and Figure 2 show the prevalence of sexual behaviour measures by time point and 
randomised arm. The additional baseline estimates exclude participants diagnosed for less 
than three months.  
 
Prevalence of CLS-D fell from revised baseline to month 4 in both arms, among MSM and 
heterosexuals. By month 24, prevalence had increased back towards the revised baseline level 
for MSM in both arms, and for heterosexuals in the immediate arm. For heterosexuals in the 
deferred arm, prevalence of CLS-D continued to fall throughout follow-up, resulting in 
higher CLS-D prevalence in the immediate versus deferred arm at month 24 [9.3% vs 5.6%, 
difference: 3.7%, 95% CI (1.0%, 6.4%), p=0.007, Chi-squared test].  
 
Patterns in CLS-D prevalence during follow-up were assessed formally in two multivariable 
logistic GEE models using data from the 4, 12 and 24 month time points. Among MSM 
(N=7003 observations), there was no interaction between randomised arm and study time 
point (p=0.24). In a model without an interaction term, CLS-D did not differ by randomised 
arm [aOR immediate vs deferred: 1.00 (0.84, 1.19) p=0.99] or calendar year [aOR per later 
year: 0.99 (0.91, 1.07) p=0.76] but differed by study time point: compared to month 4, odds 
of CLS-D was similar at month 12 [adjusted odds ratio (aOR) (95% CI): 1.05 (0.91, 1.21)] 
but higher at month 24 [aOR: 1.32 (1.10, 1.58)], global p=0.002. Among heterosexual men 
and women (N=5330 observations), the effect of randomised arm on CLS-D differed 
according to time point (p=0.017 for interaction). In a model including the interaction term, 
the effect of immediate versus deferred arm on CLS-D became greater with time: aOR (95% 
CI): 0.91 (0.66, 1.26), 1.36 (1.00, 1.85) and 1.66 (1.13, 2.43) for months 4, 12 and 24 
respectively. CLS-D did not differ with calendar year [aOR per later year: 1.05 (0.92, 1.18) 
p=0.48] but was higher for women compared to men [aOR (95% CI): 1.49 (1.15, 1.92) 
p=0.004]. 
 
Similar patterns over time were apparent when CLS was considered (Table 3 and Figure 1b). 
Prevalence of CLS-D-HIV-risk decreased over time from month 4, as participants started 
ART (Table 3 and Figure 1c). As expected this decrease was particularly dramatic in the 
immediate ART group, resulting in substantial differences in CLS-D-HIV risk between 
randomised groups at months 12 and 24. 
 
Transmission risk beliefs 
At month 12, participants in the immediate arm were more likely than those in the deferred 
arm to indicate a belief that a person on HIV treatment with undetectable VL cannot, or is 
much less likely, to transmit HIV when having unprotected sex: 48.1% versus 40.4% for 
MSM [difference: 7.7%, 95% CI (-3.7%, 11.8%), p<0.001, Chi-squared test] and 36.7% 
versus 32.2% for heterosexuals [difference: 4.5%, 95% CI (0.03%, 8.9%), p=0.049] (Table 
3). Similar differences between arms were apparent at month 24 (Table 3).  
 
For both MSM and heterosexuals, the proportion of participants who indicated this belief in a 
strong protective effect of viral suppression tended to increase over time from baseline in 
both arms.  However evidence that this belief was more likely with later calendar time was 
relatively weak. There was no trend in proportions reporting this belief over calendar time of 
questionnaire completion among MSM or heterosexuals in the immediate arm at month 12 or 
24. In the deferred arm, there was some evidence of a trend at month 24: percentages of MSM 
reporting this belief were 43.8%, 44.1%, 47.4%, 57.1% for month 24 completion years 2012-
12, 2013, 2014 and 2015 respectively (p=0.019 for trend). The corresponding percentages for 
heterosexuals were 26.8%, 39.8%, 43.9%. 36.5% (p=0.058 for trend).  
 
Transmission risk beliefs varied across regions. MSM recruited from high income settings 
were more likely than those from low/middle income settings to indicate belief in a strong 
protective effect of viral suppression [53.6% versus 30.7% at month 12, p<0.001; 58.3% 
versus 36.2% at month 24, p<0.001]. However the opposite was true for heterosexuals at 
month 12 [30.1% for high income versus 35.8% for low/middle income at month 12, 
p=0.029] with no difference at month 24 [41.7% versus 41.1%, p=0.84]. 
 
Risk behaviour related to injection drug use 
At baseline, 1.9% of MSM (40/2147) and 0.8% (15/1810) of heterosexual participants 
reported injecting recreational drugs in the past two months, of whom only three and four 
individuals respectively reported injection drug use transmission risk. At month 12, 2.0% of 
MSM (48/2355) reported injection drug use: 1.6% in the immediate arm and 2.5% in the 
deferred arm, of whom two and one respectively reported injection drug use transmission 
risk. For heterosexual individuals, 0.4% (7/1846) reported injection drug use at month 12, 
0.7% and 0.1% in the immediate and deferred arms respectively, of whom one and zero 
respectively reported injection drug use transmission risk. 
 
Discussion 
Among MSM, compared to ART deferral until a CD4<350 cells/μL or AIDS, a strategy of 
immediate ART had no impact on prevalence of HIV-serodifferent condomless sex (CLS-D) 
over the subsequent two years, or on related measures of frequency of such sex or partner 
numbers. Among heterosexual men and women, the immediate ART strategy resulted in 
modestly higher prevalence and frequency of HIV-serodifferent condomless sex at 12 and 24 
months compared to deferred ART. Among both groups, the immediate ART strategy 
resulted in a substantial reduction in prevalence of HIV-transmission risk sex by month 12, as 
the vast majority of participants in this arm had viral suppression on ART and were therefore 
classified as no risk for HIV transmission, regardless of sexual behaviour. 
 
CLS-D was the pre-defined primary endpoint in this study; this endpoint remains important 
for understanding the impact of early ART on condom use with serodifferent partners. 
However, the two additional endpoints are the most relevant for HIV and STI transmission. 
CLS-D-HIV-risk best captures HIV transmission-risk sex by accounting for viral suppression 
on ART, now known to be a critical factor in preventing transmission. CLS best captures risk 
of transmission or acquisition of other STIs, for which HIV-serostatus of partners, ART and 
HIV viral load are not relevant. These results illustrate the profound impact of early ART on 
HIV-transmission risk sex, which was less than 1% in the immediate ART arm by month 12 
(compared to 11% and 8% for MSM and heterosexuals respectively in the deferred ART arm) 
and was continued at this low level to month 24. Even though the immediate ART strategy 
resulted in a small increase in CLS-D among heterosexual participants at months 12 and 24, 
the impact of this was far outweighed by the high levels of viral suppression in this arm, 
which protected against HIV-transmission regardless of CLS-D. Even a very substantial 
increase in CLS-D would not have overturned the benefit conferred by early ART. Of note, 
this analysis suggested a benefit only from month 12, because the definition of CLS-D-HIV-
risk required ART to have been started at least 6 months previously to confer protection from 
transmission. This was based on data from the Partners Prep study which indicated a reduced 
but residual transmission risk persisting during the first 6 months of ART, due to incomplete 
viral suppression in blood and genital compartments.23 In practice, and with newer ART 
drugs, viral suppression and subsequent protection may be attained at an earlier stage after 
ART initiation. But also of note, the difference between arms in CLS-D-HIV-risk attenuated 
from month 12 to month 24, and this would continue to occur as more individuals in the 
deferral arm started ART. In terms of STI transmission risk, the strategy of early ART 
resulted in a modest increase in prevalence of CLS among heterosexual individuals at year 
two only. However, less than 2% of heterosexual participants reported more than one CLS 
partner in the recall period. Risk of STI acquisition and transmission may be less concerning 
in this context. Incidence of bacterial STIs was not assessed in START.  
 
Two previous randomised trials have assessed the impact of ART on sexual transmision 
risk;47,48 neither supported the hypothesis that ART use leads to increased condomless sex. In 
the SMART trial (2002-2006), the prevalence of ‘high-risk behaviour’ (CLS-D or injecting 
risk behaviour) was similar compared between the continuous ART and CD4-guided episodic 
ART arms.47 Among the subgroup who were not on ART at baseline, there was a reduction in 
high-risk behaviour in the first two years in the continuous compared to episodic ART arm. 
More recently ,in the TEMPRANO-ANRS12136 trial of immediate versus deferred ART 
initiation (2008-2012), the proportion of participants reporting CLS-D was similar when 
compared between randomised arms at year one.48 Many observational studies have assessed 
the association between ART and sexual behaviour among people with diagnosed HIV,24-46 
including two meta-analyses29,32 and some studies in low/middle income countries.41,43,45 The 
vast majority found no association of ART use or viral suppression with CLS-D, or found 
ART was in fact associated with lower levels of CLS-D. A few studies reported different 
findings overall, or in specific subgroups or analyses. Among sexually active women in the 
US Women’s Interagency HIV Study (1996-2001), consistent condom use was less likely to 
be reported after ART initiation compared to pre-ART, in some adjusted models.24 A small 
Australian study of HIV-serodifferent MSM couples (2001-2003) found higher levels of anal 
CLS-D among couples for whom the positive partner had suppressed VL.25 The Swiss HIV 
Cohort Study (2007-2009) found evidence of higher levels of CLS-D with stable partners 
among participants who were virally suppressed compared to those not on ART.26 In a French 
study (2000-2009), in more recent years, ART use and suppressed VL were associated with 
CLS-D among HIV-diagnosed heterosexual men with steady partners.27 In the UK ASTRA 
study (2011-12), prevalence of CLS-D among MSM on ART was higher for those with self-
reported undetectable VL compared to those without.28 Finally, a subsidiary analysis in one of 
the aforementioned meta-analyses found that an undetectable VL was associated with slightly 
higher sexual risk-taking.29  
 
Therefore previous literature suggested that, in some contexts, condom use may be influenced 
by knowledge of viral suppression, but the effect may be modest, and evidence is relatively 
weak in light of all relevant studies. These current results from START are the most 
contemporary (2010-2015) but seem broadly consistent with this synopsis, showing that 
starting ART may have modestly reduced condom use among heterosexuals. Although the 
combined heterosexual group was the predefined population of analysis, the pattern of results 
was broadly similar when men and women were examined separately (data not shown). The 
results from START and the other randomised trials have advantage that confounding is 
minimized in the comparison of the groups randomised to start or defer ART. It should also 
be noted that, as in the TEMPRANO trial, this START analysis addresses a slightly different 
question to the observational studies, as it evaluates the impact of starting ART on sexual 
behaviour over two years among people with high CD4 counts. In most of the observational 
comparisons, people on ART varied in terms of time since starting treatment and CD4 count; 
conceivably impact on sexual activity and condom use may vary according to these factors. 
However in START there was no evidence that the intervention effect on CLS-D varied 
according to time since diagnosis in heterosexual individuals or MSM. 
 
There may be a number of reasons why, in START, the effect of early ART on CLS-D was 
apparent only in the heterosexual group.  Patterns of partnerships differed for heterosexuals 
compared to MSM, with the vast majority having only one condomless sex partner during the 
recall periods. Possibly trial participants were more likely to be given advice about the 
protection from transmission conferred by viral suppression in the context of stable sero-
different relationships. Some advice may have been related to desire for conception, resulting 
in higher CLS-D among heterosexual participants on ART, and may in part explain why the 
intervention effect on CLS-D was greater among those aged under 40 years. Furthermore, the 
month 12 time point was during or after 2011 but before 2014 for the majority of participants, 
giving potential for awareness of results from HPTN 052 related to heterosexual transmission, 
but not for substantive evidence relating to MSM (results from PARNER, Opposites Attract 
and PARNTER2 first being presented in 2014-2018). However even at year two of follow-up, 
only about half of MSM and less than half of heterosexuals expressed belief in any substantial 
level of protection conferred by viral suppression; this is consistent with findings from other 
quantitative28 and qualitative21 studies. Although, in START, there was some evidence of 
increasing proportions expressing this belief over calendar time, trends were not marked or 
consistent across trial arms. Advice and information given to participants regarding viral 
suppression and transmission risks may also have differed across countries and clinical sites. 
Indeed there was evidence of significant variation in transmission risk beliefs by recruitment 
setting, which differed for MSM and heterosexuals. MSM from high income countries were 
more likely than those from low/middle income countries to express belief in a strong 
protective effect of viral suppression, whereas for heterosexuals there was some evidence of 
the opposite effect (belief more prevalent in low/middle income settings). The trial was 
carried out over a period of considerable change with regard to scientific evidence available 
on this issue, and publicity surrounding it, and these complex trends are likely to reflect this. 
Increasing emphasis on the “U=U” message17 may be leading to further changes in 
transmission risk beliefs and patterns of condom use; it is likely that the full effect of the 
current research evidence is yet to be apparent.  
 
Among MSM, in both the immediate and deferred treatment arms, CLS-D prevalence fell 
from randomization to months 4 and 12, and subsequently increased back towards the revised 
baseline levels by year two. Among heterosexual participants, a similar but less marked 
decline in CLS-D occurred from revised baseline to month 4. Other studies have reported on 
temporary reductions in sexual risk for MSM following HIV diagnosis,53,54 and so a similar 
pattern may have occurred for those individuals in START who were newly diagnosed at trial 
entry. In addition, for all participants, trial participation and regular contact with health care 
professionals and services, may have had a moderating effect on levels of condomless sex.  
 
Limitations of this study include the possibility of error or bias arising from self-reported 
sexual behaviour and incomplete or missing questionnaires, though 12 month response rates 
were high and similar between randomised arms, and questionnaires were self-completed.  
Participation in a trial with repeated monitoring of behavioural outcomes may have 
influenced condom use or it’s reporting. The measure of HIV-transmission risk sex assumes 
that the latest VL is applicable to the entire two-month recall period.  
 
In conclusion, a strategy of early ART did not impact on levels of serodifferent condomless 
sex among MSM and resulted in a small increase among heterosexual individuals. However 
in both groups, the strategy had a substantial favourable impact on HIV transmission risk 
behaviour at one year and is therefore likely to result in a marked reduction in new HIV 
infections in the initial period. The modest increase in condomless sex among the 
heterosexual group suggests the importance of continuing to monitor sexual behaviour as 
ART use expands, in order to understand any impact on other sexually transmitted infections. 
Patterns of condomless sex may have changed with increasing promotion of the U=U 
message since the START trial was conducted.  
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Table 1. Demographic and HIV-related factors at baseline, according to gender/sexual 
orientation, among 4572 participants included in the analysis* 
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*112 of 4684 randomised participants were not included in the sub-study as they did not 
complete the transmission risk behavior questionnaire at any of the three follow-up time 
points (months 4, 12 and 24).  ~Missing values: n=57 for time since diagnosis; n=8 for 
baseline VL.  BL=baseline 
Table 2. Completion of transmission risk behaviour questionnaire, prevalence of ART 
use and VL≤200c/mL, during follow-up by randomized arm and gender/sexual 
orientation 
 MSM (N=2562) Heterosexual men 
(N=788) 
Women (N=1222) 
  IMM DEF IMM DEF IMM DEF 
Baseline 
N with TRB~ 





























4 months  
N with TRB~ 






























12 months  
N with TRB~ 
































24 months  
N with TRB~ 






























~TRB=transmission risk behaviour questionnaire. ART status (on/off ART) determined at the 
date of the relevant TRB CRF 
*VL is the latest VL up to the date of the relevant TRB CRF. VL missing for 5 MSM and 3 
women at baseline 
 
Table 3. Sexual behaviour and transmission risk beliefs, at baseline and during follow-
up (months 4, 12, 24, 36) according to randomised arm, among MSM and heterosexual 








Baseline Baseline 2$ 4 months 12 months 24 months 
N % 
(n) 






























































































































































































































































































































































































































           









































      p=0.79  p=0.35  p=0.06
6 
       p=0.019
^ 
 p=0.76^  p=0.67^ 
 





Baseline Baseline 2$ 4 months 12 months 24 months 
  N % 
(n) 
N % (n) N % (n) N % (n) N % (n) 
≥1 CLS 
partner 
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       p=0.60  p<0.001  p<0.00
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IMM  842 31.6 
(266
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DEF  888 31.2 
(276
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      p=0.31  p=0.16  p=0.07
7 
       p=0.25^  p=0.52^  p=0.36^ 
*Randomised arm. IMM=immediate ART, DEF=deferred ART  
CLS=All condomless sex.  
CLS-D = Condomless sex with HIV negative (or unknown status) partner(s).  
CLS-D-HIV-risk= HIV transmission risk sex defined as CLS-D plus at least one of: not on 
ART; started ART <6 months ago; most recent VL>200c/mL; no VL in last 6 months  
$Baseline 2 estimates exclude those diagnosed less than 3 months before completing the 
baseline questionnaire, who may be reporting pre-diagnosis sexual behavior.   
P values by Chi-squared tests or Fisher’s exact test (F), or Mann-Whitney U tests for CLS-D 
acts. ^p value for change from baseline in number of CLS-D acts in subset. 
For each analysis denominators are all participants who submitted a transmission risk 
behavior questionnaire at that time point.  
#Denominators are larger for CLS-D and CLS-D-HIV-risk as these measures could be 
derived from both versions of the risk behavior questionnaire; other measures could be 
derived only from the updated version. 
Missing values: For binary measures of CLS, CLS-D, CLS-D-HIV-risk, among those who 
completed the relevant transmission risk behaviour questionnaire, missing data were assumed 
to be the absence of the behaviour (<5% cases). For transmission risk beliefs, missing data 
were excluded. For number of CLS-D acts see below. 
~Number of CLS-D acts was approximated from grouped data as follows: 2-10 times 
approximated as 6; 11-30 times approximated as 20; More than 30 times approximated as 40. 
Number of CLS-D partners was approximated from grouped data as follows: 3-5 women 
approximated as 4; more than 5 women approximated as 8.  
For those who had CLS-D, if number of CLS-D acts was missing or was less than the number 
of CLS-D partners, the value for number of CLS-D partners was used, if this was missing, 
number of CLS-D partners and number of CLS-D acts was set to one. 
£Subset is those who reported CLS-D at baseline and who had been diagnosed with HIV for 
at least 3 months at baseline. 
 
Figure 1. Effect of randomised group on CLS-D at month 12, according to baseline 
factors among MSM and heterosexual men and women 
CLS-D=condomless sex with HIV serodifferent (negative or unknown) status partner 
Odds ratio from logistic regression model 
*p value from test of interaction between each baseline factor and randomised group 
~Low/middle income (Africa; Asia; Central/South America); High income (Europe/Israel; 





B) Heterosexual men and women 
 
 
Figure 2. Prevalence of CLS-D in the past three months by time point and randomised arm among MSM, 
and heterosexual men and women: a) CLS-D; b) CLS; c) CLS-D-HIV-risk  
*Baseline estimates are also shown excluding participants who had been diagnosed with HIV for less than 3 
months.  
 For denominators by time point and p values comparing randomised arms, see Table 3.  
CLS-D=condomless sex with HIV serodifferent (negative or unknown) status partner 
CLS=condomless sex 
CLS-D-HIV-risk=HIV-transmission risk sex 
MSM= men who have sex with men; HET= heterosexual men and women IMM=immediate arm; DEF=deferred 
arm 
 
 
 
